International Multicenter Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Tolerability of BCD-033 (CJSC BIOCAD, Russia) and Rebif (Merck Serono S.p.A, Italy) After Single Subcutaneous Administration to Healthy Volunteers

Trial Profile

International Multicenter Randomized Double-blind Crossover Study of Pharmacokinetics, Pharmacodynamics and Tolerability of BCD-033 (CJSC BIOCAD, Russia) and Rebif (Merck Serono S.p.A, Italy) After Single Subcutaneous Administration to Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 06 May 2016

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Chronic inflammatory demyelinating polyradiculoneuropathy; Colorectal cancer; Crohn's disease; Glioma; Hepatitis B; Hepatitis C; Human papillomavirus infections; Multiple sclerosis; Neurological disorders; Non-small cell lung cancer; Pulmonary fibrosis; Rheumatoid arthritis; Ulcerative colitis
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Biocad
  • Most Recent Events

    • 10 Jan 2014 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov
    • 24 Jan 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top